Recce Pharmaceuticals (RCE) has been awarded a rebate on almost $10 million of research and development (R&D) by AusIndustry
The award is a big win for Recce as the R&D rebates typically only apply to work done domestically
The new finding means the company can claim around $11.65 million in rebates for research it's conducting overseasAfter a recent $27.95 million capital raise, the additional rebate funds will provide the company with a substantial funding runway
The company is planning a number of trials for its suite of synthetic antiviral compounds to fight antibiotic-resistant superbugs and emerging viral pathogens
Recce Pharmaceuticals is up 0.83 per cent and trading at $1.22
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)